• Severe allergic reaction (eg, anaphylaxis) after a previous dose of MENVEO, any component of this vaccine, or any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine is a contraindication to administration of MENVEO
    See full Important Safety Information below
Telephone Receiver Handset

Any Questions?

Contact the Vaccines
Support Center

Learn More

Diagnosis Codes

ICD-10-CM codes are used to report diseases and conditions. These will be needed on the CMS-1500 form.

View More Information

Printable Summary Sheet

This PDF provides a summary of CPT codes for GSK Vaccines.

View Summary Sheet
View all Vaccines
Coding for MENVEO
Print Page

This section provides the vaccine product codes as well as some common administration codes associated with immunization using MENVEO. Administration codes will vary based on the service provided. Please refer to your most up-to-date Current Procedural Terminology (CPT) and International Classification of Diseases (ICD) manuals for appropriate coding.


MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

Description [32] NDCs* ICD-10-CM
Code [8]**
0.5 mL
90734 MENVEO is supplied in two 0.5 mL vials that must be combined prior to administration.   Z23
Five Doses (10 Vials) in Package of 10
Five vials containing MenA lyophilized conjugate component:
Five vials containing MenCYW-135 liquid conjugate component:
Outer Carton:

NDC 58160-958-01

NDC 58160-959-01
NDC 58160-955-09
* Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC. For example, when reporting NDC 58160-820-11 to TRICARE, it becomes NDC 58160-0820-11. [14]
** With the implementation of ICD-10-CM, all vaccine-related encounters are reported as code Z23 for all vaccines given.
TIP To promote accuracy, always consult the most current Prescribing Information or product packaging when documenting NDCs.
Immunization Administration Codes (CPT) [6]
CPT Immunization administration through 18 years of age with counseling by physician or other qualified healthcare professional
90460 Immunization administration via any route, first vaccine/toxoid component
CPT Immunization administration of any vaccine for a patient through 18 years of age that is not accompanied by counseling, or for administration of vaccines to patients over 18 years of age
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), one vaccine (single or combination vaccine/toxoid)
+90472 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
Adapted from the American Medical Association, CPT 2017 Professional Edition,
Current Procedural Terminology (CPT), 2016.
TIP If reporting multiple vaccine administrations given to a patient through age 18 years on the same date along with counseling by a qualified healthcare professional, report one administration code (90460) for each vaccine administered.


MENVEO is a registered trademark of the GSK group of companies.

817906R0 March 2017

Please note that this website is provided for informational purposes only and is not intended to serve as comprehensive training on medical billing and coding. Additional training on medical coding may be required. The information on this website is believed to be accurate as of the date of publication. Users should independently verify accuracy.

Healthcare providers are responsible for making the ultimate decision on when to use a specific product based on clinical recommendations and how to bill for products and related services rendered. Consult third-party insurers' guidelines for specific information regarding the billing and reporting of services rendered.

You are encouraged to report vaccine adverse events to the US Department of Health and Human Services.
Visit to file a report, or call 1-800-822-7967.

To learn more about the
GSK Vaccines Access Program,
click here.
Contact Us